Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

Table 2 Significant changes in SDAI scores and circulating biomarker concentrations following 6 months DMARD therapy

Variable	n	Baseline		6 months		P value
Variable	n	Median	IQR	Median	IQR	P value
SDAI	140	41.39	24.10	16 .00	15.81	0.0001
CRP (μg/ml)	140	17.10	42.25	8.90	17.35	0.0001
ACPA (IU/ml)	100	516.60	1027.75	255.65	677.20	0.0001
IL-4 (pg/ml)	32	4.70	10.28	1.51	6.53	0.0075
IL-7 (pg/ml)	123	20.32	82.22	16.69	23.46	0.0013
IL-8 (pg/ml)	123	8.79	12.65	5.70	7.09	0.0001
G-CSF (pg/ml)	123	13.82	60.02	7.23	51.61	0.0083
VEGF (pg/ml)	123	168.56	441.33	92.62	167.21	0.0010
Ratio IL-1 / IL-1Ra	37	0.05	0.05	0.03	0.06	0.0130
Ratio IL-17 / IL-10	30	10.42	15.61	3.72	3.81	0.0001

ISSN: 1471-2474